Last reviewed · How we verify
Trastuzumab Biosimilar ABP 980
Trastuzumab Biosimilar ABP 980 is a Small molecule drug developed by West German Study Group. It is currently in Phase 2 development. Also known as: Trazimera®.
At a glance
| Generic name | Trastuzumab Biosimilar ABP 980 |
|---|---|
| Also known as | Trazimera® |
| Sponsor | West German Study Group |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J) (PHASE2)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (PHASE2)
- Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery (PHASE2)
- Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer (PHASE1, PHASE2)
- TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (PHASE2)
- An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis (PHASE4)
- Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trastuzumab Biosimilar ABP 980 CI brief — competitive landscape report
- Trastuzumab Biosimilar ABP 980 updates RSS · CI watch RSS
- West German Study Group portfolio CI
Frequently asked questions about Trastuzumab Biosimilar ABP 980
What is Trastuzumab Biosimilar ABP 980?
Trastuzumab Biosimilar ABP 980 is a Small molecule drug developed by West German Study Group.
Who makes Trastuzumab Biosimilar ABP 980?
Trastuzumab Biosimilar ABP 980 is developed by West German Study Group (see full West German Study Group pipeline at /company/west-german-study-group).
Is Trastuzumab Biosimilar ABP 980 also known as anything else?
Trastuzumab Biosimilar ABP 980 is also known as Trazimera®.
What development phase is Trastuzumab Biosimilar ABP 980 in?
Trastuzumab Biosimilar ABP 980 is in Phase 2.
Related
- Manufacturer: West German Study Group — full pipeline
- Also known as: Trazimera®
- Compare: Trastuzumab Biosimilar ABP 980 vs similar drugs
- Pricing: Trastuzumab Biosimilar ABP 980 cost, discount & access